-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
O3/r0s5wVkWBbvWtcBgKUhc2MlKWdDr9jm3o9cS/Cx/Z+g1mkH01yvQ/7bur3WhV
pG8QKRmkgU8sXglWOXgg/w==
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 FORM 10-Q (Mark One)
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2006 or
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the transition period from ________to _________
Commission File Number 0-21229
Stericycle, Inc.
28161 North Keith Drive
(847) 367-5910
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934
during the preceding 12 months (or for such shorter period that the registrant
was required to file reports), and (2) has been subject to such filing
requirements for the past 90 days. YES [X] NO [ ]
Indicate by check mark whether the registrant is a large accelerated filer, and accelerated
filer, or a non-accelerated filer. See the definition of "accelerated filer and large accelerated
filer" in Rule 12b-2 of the Exchange Act. (Check one)
Large accelerated filer [X] Accelerated filer [ ] Non-Accelerated filer [ ]
Indicate by check mark whether the Registrant is a shell company (as defined in Exchange Act
Rule 12b-2). YES [] NO [X]
As of November 7, 2006 there were 44,379,100 shares of the Registrant's Common Stock outstanding.
Stericycle, Inc.
PART I -- FINANCIAL INFORMATION ITEM 1. FINANCIAL STATEMENTS
STERICYCLE, INC. AND SUBSIDIARIES
The accompanying notes are an integral part of these financial statements
STERICYCLE, INC. AND SUBSIDIARIES
The accompanying notes are an integral part of these financial statements
STERICYCLE, INC. AND SUBSIDIARIES
The accompanying notes are an integral part of these financial statements
STERICYCLE, INC. AND SUBSIDIARIES Unless the context requires otherwise, "we", "us" or "our" refers to
Stericycle, Inc. and its subsidiaries on a consolidated basis. NOTE 1--BASIS OF PRESENTATION The accompanying condensed consolidated financial statements have been
prepared pursuant to the rules and regulations of the Securities and Exchange
Commission. Certain information and footnote disclosures normally included in
annual consolidated financial statements prepared in accordance with generally
accepted accounting principles have been condensed or omitted pursuant to such
rules and regulations; but the Company believes the disclosures in the
accompanying condensed consolidated financial statements are adequate to make
the information presented not misleading. In our opinion, all adjustments
necessary for a fair presentation for the periods presented have been reflected
and are of a normal recurring nature. These condensed consolidated financial
statements should be read in conjunction with the Consolidated Financial
Statements and notes thereto for the year ended December 31, 2005, as filed with
our Annual Report on Form 10-K for the year ended December 31, 2005. The results
of operations for the three and nine months ended September 30, 2006 are not
necessarily indicative of the results that may be achieved for the entire year
ending December 31, 2006. NOTE 2--ACQUISITIONS During the quarter ended September 30, 2006, we completed the acquisition
of three domestic medical waste businesses, one acquisition of a pharmaceutical
returns (reverse distribution) business and our Mexican subsidiary completed two
acquisitions of medical waste businesses. The three domestic medical waste treatment businesses acquired include
selected assets of A Nationwide Medical Waste Management, Inc. (also known as
"Nationwide Management"), which operated a medical waste business in
Florida; selected assets of Central Valley Medical Disposal, Inc. (also known as
"California Medical Disposal, Inc."), which operated a medical waste
business in California; and selected assets of Medical Microwave, Inc., which
operated a medical waste business in New Jersey. In addition we acquired
selected assets of Excess Management Systems, Inc. (also known as "One
Source"), which operated a pharmaceutical returns business in Florida. Our Mexican subsidiary, Medam S.A. de C.V. acquired selected assets of Salud
Y Ecologia Nuevo Milenio, S.A. de C.V., which operated a medical waste business
in Mexico and acquired all of the stock of International Waste Consultants, S.A.
de C.V., which operated a medical waste business in Mexico. During the quarter ended June 30, 2006, our Canadian subsidiary, Stericycle,
Inc., (a New Brunswick corporation), acquired selected assets of Mr. Shredding
Waste Management LTD., which operated a medical waste business in the New
Brunswick province of Canada. In addition, our Mexican subsidiary, Medam S.A. de
C.V. acquired selected assets of Biocen, S.A. de C.V., which operated a medical
waste business in Mexico. On February 27, 2006, our U.S. subsidiary, Stericycle International Ltd.,
acquired all of the stock of Sterile Technologies Group Limited ("STG"), for
approximately $131.0 million, of which $114.0 million was paid in cash and $17.0
million was paid by the assumption of debt. STG operates medical waste
businesses in the United Kingdom and the Republic of Ireland. In addition during the quarter ended March 31, 2006, our Mexican subsidiary,
Medam S.A. de C.V. acquired selected assets of Desarrollo Y Calidad Ambiental,
S.A. de C.V. (formerly known as Dycasa), which operated a medical waste business
in Mexico. In addition, our United Kingdom subsidiary, Stericycle International
Ltd. and our Canadian subsidiary, Stericycle, Inc., acquired all of the stock of
Habitat Ecologico S.A., which operates a medical waste business in
Argentina. The aggregate net purchase price of all our acquisitions during the nine
months ended September 30, 2006 was approximately $171.7 million, of which
$142.9 million was paid in cash, $28.0 million was paid by the issuance of notes
and the assumption of debt and $0.8 million was paid by the issuance of shares
of our common stock. The various purchase prices have been allocated to
goodwill and intangible assets and are preliminary pending completion of asset
valuations. For financial reporting purposes these acquisition transactions were
accounted for using the purchase method of accounting. The results of
operations of these acquired businesses have been included in the consolidated
statements of income from the dates of the acquisition. These acquisitions
resulted in the recognition of goodwill in our financial statements because the
purchase price reflects the complimentary strategic fit that the acquired
business brings to us. NOTE 3--STOCK BASED COMPENSATION In December 2004, the Financial Accounting Standards Board issued
Statement of Financial Accounting Standards ("SFAS") No. 123R, Share-
Based Payment ("SFAS No. 123R"). SFAS No. 123R is a revision of SFAS No.
123, Accounting for Stock-Based Compensation ("SFAS No. 123"), and supersedes
Accounting Principles Board Opinion No. 25, Accounting for Stock Issued to
Employees ("APB No. 25"), and its related implementation guidance. No stock
based compensation expense was recognized in 2005 for stock options issued in
connection under our stock option plans and through our employee stock purchase
plan ("ESPP") under the "intrinsic value" rules in APB No. 25. On
January 1, 2006, we adopted the provisions of SFAS No. 123R using the modified
prospective method. SFAS No. 123R requires entities to recognize compensation
expense for awards of equity instruments to employees based on the grant-date
fair value of those awards (with limited exceptions). SFAS No. 123R also
requires the benefits of tax deductions in excess of recognized compensation
expense to be reported as a financing cash flow, rather than as an operating
cash flow as prescribed under the prior accounting rules. This requirement
reduces net operating cash flow and increases net financing cash flows in
periods after adoption. Total cash flow remains unchanged from what would have
been reported under prior accounting rules. Stock Plans We have adopted five stock option plans: (i) the 2005 Incentive Stock
Option Plan (the "2005 Plan"), which our stockholders approved in April 2005;
(ii) the 2000 Nonstatutory Stock Option Plan (the "2000 Plan"), which our Board
of Directors adopted in February 2000; (iii) the 1997 Stock Option Plan (the
"1997 Plan"), which our stockholders approved in April 1997; (iv) the Directors
Stock Option Plan (the "Directors Plan"), which our stockholders approved in
July 1996 (prior to our initial public offering in August 1996 and which expired
in May 2006); and (v) the 1995 Incentive Compensation Plan (the "1995 Plan"),
which our stockholders approved in September 1995 (and which expired in July
2005). The 2005 Plan authorizes awards of stock options and stock appreciation
rights for a total of 2,400,000 shares; as amended, the 2000 Plan authorizes
stock option grants for a total of 3,500,000 shares; the 1997 and 1995 Plans
each authorize stock option grants for a total of 3,000,000 shares; and as
amended, the Directors Plan authorizes stock option grants for a total of
1,170,000 shares. The 2005 Plan provides for the grant of nonstatutory stock options ("NSOs")
and incentive stock options intended to qualify under section 422 of the
Internal Revenue Code ("ISOs") as well as stock appreciation rights; the 2000
Plan provides for the grant of NSOs; the 1997 and 1995 Plans each provide for
the grant of NSOs and ISOs; and the Directors Plan provides for the grant of
NSOs. The 2005 Plan authorizes awards to our officers, employees and consultants
and, following the expiration of the Directors Plan in May 2006, to our
directors; the 2000 Plan authorizes stock option grants to our employees and
consultants but not to our officers and directors; the 1997 and 1995 Plans each
authorize stock option grants to our officers, directors, employees and
consultants; and the Directors Plan authorizes stock option grants to our
outside directors. Stock Options Options granted to officers and employees generally vest over five
years. During 2005 and 2006, options granted to officers and employees generally
vested at the rate of 20% of the option shares on each of the first five
anniversaries of the option grant date. During 2004, options granted to officers
and employees generally vested at the rate of 20% of the option shares on the
first anniversary of the option grant date and then at the rate of 1/60 of the
option shares for each of the next 48 months. Expense related to the graded
vesting options is recognized using the straight-line method over the vesting
period. The exercise price per share of an option granted under any of our stock
option plans may not be less than the closing price of a share of our common
stock on the date of grant. The maximum term of an option granted under any plan
may not exceed 10 years. An option may be exercised only when it is vested and,
in the case of an option granted to an employee (including an officer), only
while he or she remains an employee and for a limited period following the
termination of his or her employment. New shares are issued upon exercise of
stock options. Option activity for the first nine months of 2006 is summarized
as follows: The aggregate intrinsic value in the table above represents the total pre-tax
intrinsic value (the difference between our closing stock price on the last day
of trading for the nine months ended September 30, 2006 and the exercise price,
multiplied by the number of in-the-money options) that would have been received
by the option holders assuming all option holders had exercised their options on
September 30, 2006. This amount changes based on the fair market value of our
stock. The total intrinsic value of options exercised for the nine months ended
September 30, 2006 was $30.7 million. The Black-Scholes option-pricing model was used in determining the fair value
of each option grant. The expected term of options granted is based on
historical experience. Expected volatility is based upon historical experience.
The expected dividend yield is zero. The risk-free interest rate is based on the
average of the U.S. Treasury three and five-year yield rates. Assumptions used
in the Black-Scholes model are presented below: Stock Based Compensation Expense As a result of adopting SFAS No. 123R, total pre-tax stock based
compensation expense in the condensed consolidated statements of income for the
three and nine months ended September 30, 2006 was $2.7 million and $7.9
million, respectively. Net income for the three and nine months ended September
30, 2006 was negatively impacted by $1.6 million and $4.8 million respectively,
because we were no longer accounting for stock-based compensation under APB No.
25. Basic and diluted earnings per share for the quarter ended September 30,
2006 of $0.62 and $0.61, respectively, were negatively impacted by $0.04 each
due to the adoption of SFAS No. 123R. For the nine months ended September 30,
2006 basic and diluted earnings per share of $1.72 and $1.68, respectively, were
negatively impacted by $0.12 each due to the adoption of SFAS No. 123R. The pre-
tax stock based compensation consisted of the following: As of September 30, 2006, there was $20.1 million of total unrecognized
compensation expense, related to non-vested option awards, which is expected to
be recognized over a weighted-average period of 1.88 years. In October 2000, our Board of Directors adopted the Stericycle, Inc. Employee
Stock Purchase Plan (the "ESPP") effective as of July 1, 2001. Our stockholders
approved the ESPP in May 2001. The ESPP authorizes 300,000 shares of our common
stock to be purchased by employees at a 15% discount from the market price of
the stock through payroll deductions during two six-month offerings each year.
An employee who elects to participate in an offering is granted an option on the
first day of the offering for a number of shares equal to the employee's payroll
deductions under the ESPP during the offering period (which may not exceed
$5,000) divided by the option price per share. The option price per share is the
lower of 85% of the closing price of a share of our common stock on the first
trading day of the offering period or 85% of the closing price on the last
trading day of the offering period. Every employee who has completed one year's
employment as of the first day of an offering and who is a full-time employee,
or a part-time employee who customarily works at least 20 hours per week, is
eligible to participate in the offering. Prior to the adoption of SFAS No. 123R,
the ESPP was accounted for as a non-compensatory plan and no expense was
recognized. Under SFAS No. 123R expense is recognized. Prior to the adoption of SFAS No. 123R, we accounted for our stock plans
using the intrinsic value method in accordance with APB No. 25 and applied the
disclosure-only provisions of SFAS No. 123. Accordingly, no stock based
compensation expense had been recognized in the condensed consolidated
statements of income. The pro forma disclosures permitted under SFAS No. 123 are
no longer an alternative to financial statement recognition. In 2005, in
anticipation of the adoption of SFAS No. 123R on January 1, 2006, we reviewed
the values of the variables used to determine the fair value of our stock
options granted in 2003, 2004 and 2005. We determined that the values of the
expected volatility, weighted average expected life of the option and risk-free
interest rate variables should be modified slightly in order to provide a better
estimate of the fair value of the employee stock options. The modifications
resulted in an immaterial reduction in the pro forma stock option expense
originally reported for the three and nine months of 2005. The following revised
assumptions were used in 2005, 2004 and 2003: expected volatility of 32% in
2005, 42% in 2004 and 49% in 2003; risk-free interest rates of 4.05% in 2005,
3.43% in 2004, and 2.97% in 2003; a dividend yield of 0%; and a weighted-average
expected life of the option of 52 months in 2005, 56 months in 2004 and 56
months in 2003. The following table presents pro forma income and income per share data as if
a fair value based method had been used to account for stock based
compensation: NOTE 4--COMMON STOCK. During the quarter ended September 30, 2006, options to purchase 331,764
shares of common stock were exercised at prices ranging from $4.00 - $62.31 per
share. During the quarter, we repurchased on the open market and subsequently
cancelled 174,858 shares of common stock. The weighted average repurchase price
was $62.73 per share. During the quarter ended June 30, 2006, options to purchase 61,556 shares of
common stock were exercised at prices ranging from $6.38 - $50.14 per share.
During the quarter, we repurchased on the open market and subsequently cancelled
62,600 shares of common stock. The weighted average repurchase price was $62.61
per share. During the quarter ended March 31, 2006, options to purchase 282,080 shares
of common stock were exercised at prices ranging from $4.00 - $62.31 per share.
During the quarter, we repurchased on the open market and subsequently cancelled
193,100 shares of common stock. The weighted average repurchase price was $57.99
per share. NOTE 5--NET INCOME PER COMMON SHARE The following table sets forth the computation of basic and diluted net
income per share (in thousands, except share and per share data): NOTE 6--COMPREHENSIVE INCOME The components of total comprehensive income are net income, the change
in cumulative currency translation adjustments, and gains and losses on
derivative instruments qualifying as cash flow hedges. The following table sets
forth the components of total comprehensive income (in thousands): NOTE 7--GUARANTEE We have guaranteed a loan to the Azoroa Bank in Japan on behalf of
Shiraishi-Sogyo Co. Ltd. ("Shiraishi"). Shiraishi is a customer in Japan that is
expanding their medical waste management business and has a five-year loan with
a current balance of $5.3 million with the Azoroa Bank that expires in June
2009. NOTE 8--GOODWILL We have two geographical reporting segments, United States and Foreign
Countries, both of which have goodwill. The changes in the carrying amount of
goodwill, net of amortization, for the nine months ended September 30, 2006 were
as follows (in thousands): During the quarter ended June 30, 2006 we performed our annual goodwill
impairment evaluation for both of our reportable units, United States and
Foreign Countries, and determined that none of our recorded goodwill was
impaired. We complete our annual impairment analysis of our indefinite lived
intangibles (facility permits) during the quarter ended December 31 of each
year. NOTE 9--LEGAL PROCEEDINGS We operate in a highly regulated industry and must deal with regulatory
inquiries or investigations from time to time that may be instituted for a
variety of reasons. We are also involved in a variety of civil litigation from
time to time. In June 2006, the United Kingdom Office of Fair Trading ("OFT")
referred to the United Kingdom Competition Commission (the "Competition
Commission") the acquisition by our subsidiary, Stericycle International,
LLC, in February 2006 of all of the stock of The Sterile Technologies Group
Limited ("STG"), an Irish company providing medical waste management
services in Ireland and the United Kingdom. Under the terms of the OFT's
referral, the Competition Commission is to decide whether, as a result of the
STG acquisition, there has been or is expected to be a substantial lessening of
competition in one or more markets in the United Kingdom for healthcare risk
waste services, and if so, what remedial or other actions, if any, should be
taken or recommended by the Competition Commission. On October 19, 2006, the Competition Commission issued provisional findings
that the STG acquisition has resulted, or may be expected to result, in a
substantial lessening of competition in the market for healthcare risk waste
services requiring incineration in five geographical areas of England and Wales.
The Competition Commission also issued a notice of possible remedies, including
(i) a complete divestiture of STG's operations in England and Wales, or (ii) a
complete divestiture of STG's incinerators in England and Wales or (iii) a
divestiture of STG's incinerators serving customers in the affected geographical
areas. We disagree with the Competition Commission's provisional findings and
the appropriateness of its possible remedies. We have until November 10, 2006 to
provide the Competition Commission with our reasons why its provisional findings
should not become final and our views of its possible remedies. The Competition
Commission's final report is due no later than December 12, 2006. NOTE 10--NEW ACCOUNTING STANDARDS In September 2006, the Financial Accounting Standards Board ("FASB")
issued SFAS No. 157, "Fair Value Measurements ("SFAS No. 157")." SFAS
No. 157 defines fair value, establishes a framework for measuring fair value and
requires enhanced disclosures about fair value measurements. SFAS No. 157
requires companies to disclose the fair value of their financial instruments
according to a fair value hierarchy as defined in the standard. Additionally,
companies are required to provide enhanced disclosure regarding financial
instruments, including a reconciliation of the beginning and ending balances
separately for each major category of assets and liabilities. SFAS No. 157 is
effective for financial statements issued for fiscal years beginning after
November 15, 2007, and interim periods within those fiscal years. We are
currently evaluating the impact of SFAS No. 157 on our consolidated results of
operations and financial condition. In February 2006, FASB issued SFAS No. 155, "Accounting for Certain Hybrid
Financial Instruments ("SFAS No. 155")." SFAS No. 155 permits fair
value remeasurement for any hybrid financial instrument that contains an
embedded derivative that otherwise would require bifurcation. As of September
30, 2006, we did not have any hybrid financial instruments subject to fair value
election under SFAS No. 155. We are required to adopt SFAS No. 155 effective at
the beginning of 2007. In June 2006, the FASB issued Interpretation No. 48, "Accounting for
Uncertainty in Income Taxes - an interpretation of FASB Statement No. 109" (FIN
48). This interpretation clarifies the accounting for uncertainty in income
taxes recognized in an enterprise's financial statements in accordance with SFAS
No. 109, "Accounting for Income Taxes." This Interpretation prescribes a
recognition threshold and measurement attribute for the financial statement
recognition and measurement of a tax position taken or expected to be taken in a
tax return. This Interpretation also provides guidance on derecognition,
classification, interest and penalties, accounting in interim periods,
disclosure, and transition. FIN 48 is effective for fiscal years beginning after
December 15, 2006. We are currently evaluating the impact of FIN 48 on our
consolidated results of operations and financial condition. NOTE 11--GEOGRAPHIC INFORMATION Management has determined that we have two reportable segments, United
States and Foreign Countries based on our consideration of the criteria detailed
in FASB Statement No. 131, "Disclosures about Segments of an Enterprise and
Related Information." Revenues are attributed to countries based on the location
of customers. Inter-company revenues recorded by the United States for work
performed in Canada, which are immaterial, are eliminated prior to reporting
United States revenues. The same accounting principles and critical accounting
policies are used in the preparation of the financial statements for both
reporting segments. Detailed information for our United States reporting segment is as
follows Detailed information for our Foreign Countries reporting segment is as
follows: NOTE 12-SENIOR CREDIT FACILITY On July 31, 2006, we and certain of our subsidiaries entered into a new
credit agreement with Bank of America, N.A.,and other lenders
party to the Credit Agreement. The new credit agreement is in effect an
amendment of our prior senior unsecured credit facility. The new credit agreement (i) reduces our costs of borrowing by using a more
favorable pricing grid; (ii) increases our revolving credit facility from $550
million to $650 million; (iii) increases the "accordion" (the amount
for which we may request an increase in the size of our revolving credit
facility) from $100 million to $200 million, (iv) increases the letter of credit
sublimit from $150 million to $200 million; (v) increases the foreign currency
sublimit from $125 million to $200 million; (vi) increases the debt-to-EBITDA
covenant from 3.00:1.00 to 3.75:1.00; and (vii) extends the maturity date of our
borrowings from June 30, 2010 to July 31, 2011. The new credit agreement reduces our costs of borrowing by reducing the
applicable margin that is added to the relevant interest rate that we are
charged. Our borrowings bear interest at fluctuating interest rates determined,
at our election in advance for any quarterly or other applicable interest
period, by reference to (i) a "base rate" (the higher of the prime
rate at Bank of America, N.A. or 0.5% above the rate on overnight federal funds
transactions) or (ii) the London Interbank Offered Rate, or LIBOR, plus, in
either case, the applicable margin within the relevant range of margins provided
in our credit agreement. Under the new credit agreement, the applicable margin
is based on (i) our consolidated leverage ratio, or, if our long-term non-credit
enhanced debt has been rated by Standard & Poors, (ii) our S&P debt
rating, whichever margin is more favorable to us. As of September 30, 2006, the
margin for interest rates on borrowings under our new credit facility was 0.0%
on base rate loans and 0.875% on LIBOR loans. The new credit agreement contains customary events of default, including our
failure to pay any principal, interest or other amount when due, our violation
of certain of our affirmative covenants or any of our negative covenants, a
breach of our representations and warranties, or a change of control. Upon the
occurrence of an event of default, payment of our indebtedness may be
accelerated and the lending commitments under the credit agreement may be
terminated. ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS We were incorporated in March 1989. We provide compliance services
including regulated medical waste collection, transportation and treatment
services to our customers and related training and education programs and
consulting services. We also sell ancillary supplies and transport
pharmaceuticals, photographic chemicals, lead foil and amalgam for recycling in
selected geographic service areas. In addition, we have begun to provide
pharmaceutical returns services, and we are also expanding into international
markets through acquisitions, joint ventures and/or by licensing our proprietary
technology and selling associated equipment. THREE MONTHS ENDED SEPTEMBER 30, 2006 COMPARED TO THREE MONTHS ENDED
SEPTEMBER 30, 2005 The following summarizes (in thousands, except per share data) the Company's
operations: Revenues. Revenues increased $50.1 million or 32.7%, to $203.3
million during the quarter ended September 30, 2006 from $153.2 million during
the comparable quarter in 2005 as a result of acquisitions completed during both
2005 and 2006, and our continued strategy of focusing on sales to higher-margin
small quantity customers. During the quarter ended September 30, 2006,
acquisitions less than one year old contributed approximately $30.0 million in
revenue. For the quarter, our base internal revenue growth for small quantity
customers increased approximately 12% and revenues from large quantity customers
increased by approximately 9% as we continued to increase our number of Bio
Systems customers. We believe the size of the regulated medical waste market in the United
States remained relatively stable during the quarter. Cost of revenues. Cost of revenues increased by $27.2 million
to $112.7 million during the quarter ended September 30, 2006 from $85.6 million
during the comparable quarter in 2005. This increase is primarily related to our
increased revenues during 2006 compared to 2005. Our gross margin percentage
increased to 44.5% during the quarter from 44.1% during the comparable quarter
in 2005 due to an increase in gross margins on our domestic business as we
continued to realize improvements from our ongoing programs to improve the
margins on our large and small quantity business. In cost of revenues, there was
$0.2 million in stock compensation expense that negatively impacted the gross
margin percentage by 0.1% in the quarter. Selling, general and administrative expenses. Selling, general
and administrative expenses, including acquisition related costs, increased to
$37.5 million for the quarter ended September 30, 2006 from $24.8 million for
the comparable quarter in 2005. The increase was primarily due to incremental
overhead expenses as a result of our Pharmaceutical Services acquisitions in
2005 and the acquisition of Sterile Technologies Group Limited in 2006 and
effective January 1, 2006, we adopted Statement of Financial Accounting
Standards ("SFAS") No. 123R, Share-Based Payments ("SFAS No. 123R") using the
modified prospective method, which resulted in a change in our method of
recognizing share-based compensation expense, which increased selling, general
and administrative expenses by $2.5 million. Amortization expense increased to $1.2 million during the quarter from $0.5
million in the same quarter in 2005. This increase was the result of
amortization expense related to intangible assets associated with acquisitions
completed in 2005 and 2006. Acquisition related expenses increased to $0.5
million in 2006 as compared to $0.2 million in 2005. Selling, general and
administrative expenses as a percent of revenues increased to 18.4% during the
quarter from 16.2% during the comparable quarter in 2005. Of the 2.2% increase
in selling, general and administrative expenses in comparison to the same
quarter in 2005, approximately 1.2% was the result of stock compensation expense
being recorded in 2006. Income from operations. Income from operations increased to
$53.0 million for the quarter ended September 30, 2006 from $42.0 million for
the comparable quarter in 2005. The increase was due to higher gross profit,
partially offset by higher selling, general and administrative expenses during
the quarter. Net interest expense. Net interest expense increased to $7.3
million during the quarter ended September 30, 2006 from $3.0 million during the
comparable quarter in 2005 due primarily to increased debt levels related to
acquisitions as well as higher interest rates on our senior unsecured revolving
credit facility. Income tax expense. Income tax expense increased to $17.6
million for the quarter ended September 30, 2006 from $15.1 million for the
comparable quarter in 2005. The increase was due to higher taxable income. The
effective tax rates for the quarters ended September 30, 2006 and 2005 were
39.0% and 39.2%, respectively. NINE MONTHS ENDED SEPTEMBER 30, 2006 COMPARED TO NINE MONTHS ENDED
SEPTEMBER 30, 2005 The following summarizes (in thousands, except per share data) the Company's
operations: Revenues. Revenues increased $138.0 million or 31.2%, to $580.9
million during the nine months ended September 30, 2006 from $442.9 million
during the comparable period in 2005 as a result of acquisitions completed
during both 2005 and 2006, and our continued strategy of focusing on sales to
higher-margin small quantity customers. During the nine months ended September
30, 2006, acquisitions less than one year old contributed approximately $87.6
million to our increase in revenues from 2005. For the nine months ended
September 30, 2006, our base internal revenue growth for small quantity
customers increased approximately 11% and revenues from large quantity customers
increased by approximately 9% as we continued to increase our number of Bio
Systems customers. We believe the size of the regulated medical waste market in the United
States remained relatively stable during the period. Cost of revenues. Cost of revenues increased by $75.0 million
to $324.1 million during the nine months ended September 30, 2006 from $249.1
million during the comparable period in 2005. This increase is primarily related
to our increased revenues during 2006 compared to 2005. Our gross margin
percentage increased to 44.2% during the period from 43.8% during the same
period in 2005 due to an increase in gross margins on our domestic business as
we continued to realize improvements from our ongoing programs to improve the
margins on our large and small quantity business. In cost of revenues, there was
$0.6 million in stock compensation expense that negatively impacted the gross
margin percentage by 0.1% in the period. Selling, general and administrative expenses. Selling, general
and administrative expenses, including acquisition related costs, increased to
$108.8 million for the nine months ended September 30, 2006 from $69.9 million
for the comparable period in 2005. The increase was primarily due to incremental
overhead expenses as a result of our Pharmaceutical Services acquisitions in
2005 and the acquisition of Sterile Technologies Group Limited in 2006.
Effective January 1, 2006, we adopted Statement of Financial Accounting
Standards ("SFAS") No. 123R, Share-Based Payments ("SFAS No. 123R") using the
modified prospective method, which resulted in a change in our method of
recognizing share-based compensation expense, which increased selling, general
and administrative expenses by $7.3 million. Amortization expense increased to $2.5 million during the nine months ended
September 30, 2006 from $1.2 million in the same period in 2005. This increase
was the result of amortization expense related to intangible assets associated
with acquisitions completed in 2005 and 2006. Acquisition related expenses
increased to $1.8 million in 2006 as compared to $0.4 million in 2005 due to
acquisitions that occurred in late 2005 and in 2006. Selling, general and
administrative expenses as a percent of revenues increased to 18.7% from 15.8%
during the comparable period in 2005. Of the 2.9% increase in selling, general
and administrative expenses, approximately 1.2% was the result of stock
compensation expense being recorded in 2006. Write-down of fixed assets. During the nine months ended
September 30, 2006 we had a $0.3 million non-cash write-down of equipment
compared to $0.9 million in the comparable period in 2005. Income from operations. Income from operations increased to
$147.7 million for the nine months ended September 30, 2006 from $123.0 million
for the comparable period in 2005. The increase was due to higher gross profit,
partially offset by higher selling, general and administrative expenses during
the period. During the nine months ended September 30, 2006 we had a $0.3
million non-cash write-down of equipment. Income from operations as a percentage
of revenue decreased to 25.4% during the period from 27.8% during the same
period in 2005. Write-down of investment. During the nine months ended
September 30, 2006 we had a $1.0 million non-cash write-down of an investment in
securities. Net interest expense. Net interest expense increased to $20.0
million during the nine months ended September 30, 2006 from $8.4 million during
the comparable period in 2005 due primarily to increased debt levels related to
acquisitions as well as higher interest rates on our senior unsecured revolving
credit facility. Income tax expense. Income tax expense increased to $48.7
million for the nine months ended September 30, 2006 from $43.9 million for the
comparable period in 2005. The increase was due to higher taxable income. The
effective tax rates for the nine months ended September 30, 2006 and 2005 were
39.0% and 39.2%, respectively. LIQUIDITY AND CAPITAL RESOURCES On July 31, 2006, we amended and restated our $550.0 million senior
unsecured revolving credit facility maturing in June 2010. The amended credit
facility was increased to $650.0 million and matures on July 31, 2011. At
September 30, 2006, the margin for interest rates on borrowings under our new
credit facility was 0.0% on base rate loans and 0.875% on LIBOR loans. Our
credit facility requires us to comply with various financial, reporting and
other covenants and restrictions, including a restriction on dividend payments.
At September 30, 2006, we were in compliance with all of our financial debt
covenants. As of September 30, 2006, we had $360.0 million of borrowings
outstanding under our senior unsecured credit facility, which includes foreign
currency borrowings of $7.0 million. In addition, we had $60.6 million committed
to outstanding letters of credit. The weighted average rate of interest on the
unsecured revolving credit facility was 6.15% per annum. At September 30, 2006,
we had $90.8 million in other debt outstanding, which includes promissory notes
issued in connection with acquisitions during 2003 through 2006 and foreign
subsidiary bank debt. Working Capital. At September 30, 2006, our working capital
decreased $12.5 million to $32.8 compared to working capital of $45.3 million at
December 31, 2005. This decrease was primarily the result of higher accrued
liabilities and current portion of long-term debt partially offset by higher
accounts receivable balances. Net Cash Provided or Used. Net cash provided by operating
activities was $114.7 million during the nine months ended September 30, 2006
compared to $90.9 million for the comparable period in 2005. This increase was
primarily due to higher net income adjusted for stock compensation expense and
depreciation, plus an increase in accrued liabilities partially offset by
increases in accounts receivable and accounts payable. As a result of adopting
SFAS No. 123R effective January 1, 2006, we recorded $7.9 million in stock
compensation expense for employee stock options and employee stock purchase
program for the nine months ended September 30, 2006. SFAS No. 123R also
requires the benefits of tax deductions in excess of recognized compensation
expense to be reported as a financing cash flow, rather than as an operating
cash flow as prescribed under the prior accounting rules. This requirement
reduces net operating cash flow and increases net financing cash flows in
periods after adoption. Total cash flow remains unchanged from what would have
been reported under prior accounting rules. As a result, $7.8 million in tax
benefits on stock options exercised was reported as cash provided by financing
activities for the nine months ended September 30, 2006 compared to $6.1 million
reported as cash provided by operating activities for the nine months ended
September 30, 2005. Net cash used in investing activities for the nine months ended September 30,
2006 was $170.8 million compared to $67.0 million for the comparable period in
2005. This increase is primarily attributable to an increase in payments for
acquisitions, purchases of short-term investments and higher capital
expenditures. Cash investments in acquisitions and international joint ventures
for the nine months ended September 30, 2006 were $142.9 million versus $46.9
million in the comparable period in 2005 primarily as a result of the Sterile
Technologies Group Limited acquisition. Capital expenditures were $25.6 million
for the period compared to $20.1 million during the same period in 2005. At September 30, 2006 we had approximately 9% of our treatment capacity in
North America in incineration and approximately 91% in non-incineration
technologies such as our proprietary patented ETD technology and autoclaving.
The implementation of our commitment to move away from incineration in North
America may result in a write-down of the incineration equipment as and when we
close incinerators that we are currently operating. Our commitment to move away
from incineration in North America is in the nature of a goal to be accomplished
over an undetermined number of years. Because of uncertainties relating, among
other things, to customer education and acceptance and legal requirements to
incinerate portions of the medical waste, we do not have a timetable for this
transition or specific plans to close any of our existing incinerators. Net cash provided by financing activities was $55.3 million during the nine
months ended September 30, 2006 compared to net cash used of $30.1 million for
the comparable period in 2005. This is primarily the result of higher issuances
of notes payable and borrowings under our senior unsecured credit facility to
fund acquisitions along with a reduction in the purchase of treasury stock
during the nine months ended September 30, 2006. Net cash provided by financing
activities included $7.8 million in tax benefits on stock options exercised due
to the new reporting requirements under SFAS No. 123R in classifying tax
benefits on stock options exercised as cash provided by financing activities
versus prior presentation as cash provided by operating activities. In addition,
we repurchased and subsequently cancelled 430,558 shares of common stock for
$26.1 million in cash in the nine months ended September 30, 2006 compared to
1,012,800 shares for $47.3 million in cash during the comparable period last
year. Guarantees: We have guaranteed a loan to the Azoroa Bank in
Japan on behalf of Shiraishi-Sogyo Co. Ltd ("Shiraishi"). Shiraishi is a
customer in Japan that is expanding their medical waste management business and
has a five-year loan with a current balance of $5.3 million with the Azoroa Bank
that expires in June 2009. Management currently believes no amount will be paid
under the guarantee. ITEM 3. QUALITATIVE AND QUANTITATIVE DISCLOSURES ABOUT
MARKET RISK We are subject to market risks arising from changes
in interest rates on our senior unsecured credit facility. Our interest rate
exposure results from changes in LIBOR or the base rate, which are used to
determine the applicable interest rates under our term loans and revolving
credit facility. Our potential loss over one year that would result from a
hypothetical, instantaneous and unfavorable change of 100 basis points in the
interest rate on all of our variable rate obligations would be approximately
$4.0 million on a pre-tax basis. We have exposure to currency exchange rate fluctuations between the US dollar
(USD) and UK pound sterling (GBP) related to an 11 million GBP inter-company
loan with Stericycle International, Ltd., the parent company of White Rose
Environmental. In October 2005, we elected cash flow hedge accounting treatment
on our remaining forward contracts. Both the inter-company loan balance and the
forward contracts are marked to market at the end of each reporting period and
the impact on the balances is recorded on the balance sheet to other
comprehensive income. We have exposure to commodity pricing for gas and diesel fuel for our trucks
and for the purchase of containers and boxes. We do not hedge these items to
manage the exposure. ITEM 4. CONTROLS AND PROCEDURES Disclosure Controls and Procedures Our management, with the participation of our President and Chief
Executive Officer and our Chief Financial Officer, conducted an evaluation of
the effectiveness of our disclosure controls and procedures as of the end of the
fiscal quarter covered by this Report. On the basis of this evaluation, our
President and Chief Executive Officer and our Chief Financial Officer each
concluded that our disclosure controls and procedures were effective. The term "disclosure controls and procedures" is defined in Rule 13a-14(e) of
the Securities Exchange Act of 1934 as "controls and other procedures designed
to ensure that information required to be disclosed by the issuer in the
reports, files or submits under the Act is recorded, processed, summarized and
reported, within the time periods specified in the Securities and Exchange
Commission's rules and forms." Our disclosure controls and procedures are
designed to ensure that material information relating to us and our consolidated
subsidiaries is accumulated and communicated to our management, including our
President and Chief Executive Officer and our Chief Financial Officer, as
appropriate to allow timely decisions regarding our required disclosures. Internal Control Over Financial Reporting During the quarter ended September 30, 2006, there were no changes in
our internal controls over financial reporting that have materially affected, or
are reasonably likely materially to affect, our internal controls over financial
reporting. FROM TIME TO TIME WE ISSUE FORWARD-LOOKING STATEMENTS RELATING TO SUCH
THINGS AS ANTICIPATED FINANCIAL PERFORMANCE, BUSINESS PROSPECTS, ACQUISITION
ACTIVITIES AND SIMILAR MATTERS. THESE FORWARD-LOOKING STATEMENTS MAY INVOLVE RISKS AND UNCERTAINTIES, SOME OF
WHICH ARE BEYOND OUR CONTROL (FOR EXAMPLE, GENERAL ECONOMIC CONDITIONS). OUR
ACTUAL RESULTS COULD DIFFER SIGNIFICANTLY FROM THE RESULTS DESCRIBED IN THE
FORWARD-LOOKING STATEMENTS. FACTORS THAT COULD CAUSE SUCH DIFFERENCES INCLUDE
DIFFICULTIES IN COMPLETING THE INTEGRATION OF ACQUIRED BUSINESSES, CHANGES IN
GOVERNMENTAL REGULATION OF MEDICAL WASTE COLLECTION AND TREATMENT, AND INCREASES
IN TRANSPORTATION AND OTHER OPERATING COSTS, AS WELL AS VARIOUS OTHER
FACTORS. PART II See Note 9, Legal Proceedings, in the Notes to the Condensed Consolidated
Financial Statements. (Item 1 of Part 1). ITEM 2. CHANGES IN SECURITIES, USES OF PROCEEDS AND ISSUER PURCHASES OF
EQUITY SECURITIES The following table provides information about our purchases during the
nine months ended September 30, 2006 of shares of our common stock. Issuer Purchases of Equity Securities In May 2002 our Board of Directors authorized the Company to
repurchase up to 3,000,000 shares of our common stock, in the open market or
through privately negotiated transactions, at times and in amounts in the
Company's discretion. In February 2005, at a time when we had purchased a
cumulative total of 1,478,430 shares, the Board authorized the Company to
purchase up to an additional 1,478,430 shares, thereby giving the Company the
authority to purchase up to a total of 3,000,000 additional shares. 31.1 Rule 13a-14(a)/15d-14(a) Certification of Mark C. Miller,
President and Chief Executive Officer 31.2 Rule 13a-14(a)/15d-14(a) Certification of Frank J.M. ten Brink,
Executive Vice President and Chief Financial Officer 32 Section 1350 Certification of Mark C. Miller, President and Chief
Executive Officer, and Frank J.M. ten Brink, Executive Vice President and Chief
Financial Officer SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized. Dated: November 8, 2006.
(Exact name of registrant as specified in its charter)
Lake Forest, Illinois 60045
(Address of principal executive offices including zip code)
(Registrant's telephone number, including area code)
Table of Contents
PART I. Financial Information
Page No.
Item 1. Financial Statements
Condensed Consolidated Balance Sheets as of
September 30, 2006 (Unaudited) and December 31, 2005 (Audited)
Condensed Consolidated Statements of Income
for the three and nine months ended September 30, 2006 and 2005 (Unaudited)
Condensed Consolidated Statements of Cash Flows
for the nine months ended September 30, 2006 and 2005 (Unaudited)
Notes to Condensed Consolidated Financial Statements (Unaudited)
Item 2. Management's Discussion and Analysis of Financial
Condition and Results of Operations
Item 3. Qualitative and Quantitative Disclosures about Market Risk
Item 4. Controls and Procedures
PART II. Other Information
Item 1. Legal Proceedings
Item 2. Changes in Securities, Use of Proceeds and Issuer Purchases of Equity Securities
Item 6. Exhibits
Signatures
Certifications
CONDENSED CONSOLIDATED BALANCE SHEETS
(IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA)
September 30, December 31,
2006 2005
------------ -----------
(unaudited) (audited)
ASSETS
Current assets:
Cash and cash equivalents............................................ $ 4,180 7,825
Short-term investments............................................... 3,621 720
Accounts receivable, less allowance for doubtful
accounts of $4,952 in 2006 and $4,810 in 2005...................... 136,414 103,703
Parts and supplies................................................... 7,255 5,263
Prepaid expenses..................................................... 9,404 6,523
Notes receivable..................................................... 2,942 3,164
Deferred tax asset................................................... 15,899 13,452
Other................................................................ 3,857 3,392
------------ -----------
Total current assets........................................ 183,572 144,042
------------ -----------
Property, plant and equipment, net................................... 154,287 136,220
Other assets:
Goodwill............................................................. 780,719 685,169
Intangible assets, less accumulated amortization of
$11,071 in 2006 and $8,965 in 2005................................. 129,272 61,641
Notes receivable..................................................... 12,596 10,672
Other................................................................ 9,580 9,916
------------ -----------
Total other assets................................................. 932,167 767,398
------------ -----------
Total assets................................................ $ 1,270,026 $ 1,047,660
============ ===========
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Current portion of long term debt.................................... $ 29,041 $ 12,044
Accounts payable..................................................... 26,926 27,872
Accrued liabilities.................................................. 82,439 48,450
Deferred revenue..................................................... 12,397 10,394
------------ -----------
Total current liabilities................................... 150,803 98,760
------------ -----------
Long-term debt, net of current portion............................... 422,526 348,841
Deferred income taxes................................................ 82,308 71,549
Other liabilities.................................................... 9,116 6,876
Common shareholders' equity:
Common stock (par value $.01 per share, 80,000,000
shares authorized, 44,404,559 issued and outstanding in
in 2006, 44,149,722 issued and outstanding in 2005)................ 444 442
Additional paid-in capital........................................... 262,595 259,075
Accumulated other comprehensive income............................... 4,439 546
Retained earnings.................................................... 337,795 261,571
------------ -----------
Total shareholders' equity........................................... 605,273 521,634
------------ -----------
Total liabilities and shareholders' equity......................... $ 1,270,026 $ 1,047,660
============ ===========
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA)
(unaudited)
Three Months Ended Nine Months Ended
September 30, September 30,
------------------------ ------------------------
2006 2005 2006 2005
----------- ------------ ----------- ------------
Revenues........................................................ $ 203,267 $ 153,176 $ 580,940 $ 442,902
Costs and expenses:
Cost of revenues.............................................. 107,700 81,513 309,426 236,856
Selling, general and
administrative expenses..................................... 34,912 23,300 101,549 65,965
Depreciation and amortization................................. 7,101 5,365 20,109 15,735
Write-down of fixed assets.................................... -- 872 300 872
Acquisition related costs..................................... 519 174 1,814 444
----------- ----------- ----------- -----------
Total costs and expenses................................... 150,232 111,224 433,198 319,872
----------- ----------- ----------- -----------
Income from operations.......................................... 53,035 41,952 147,742 123,030
----------- ----------- ----------- -----------
Other income (expense):
Interest income............................................... 490 228 997 428
Interest expense.............................................. (7,810) (3,251) (20,969) (8,848)
Write-off of deferred financing fees.......................... -- -- -- (197)
Write-down of investment in securities........................ -- -- (1,000) --
Other expense................................................. (580) (489) (1,810) (2,296)
----------- ----------- ----------- -----------
Total other income (expense)............................... (7,900) (3,512) (22,782) (10,913)
----------- ----------- ----------- -----------
Income before income taxes...................................... 45,135 38,440 124,960 112,117
Income tax expense.............................................. 17,603 15,057 48,735 43,937
----------- ----------- ----------- -----------
Net income...................................................... $ 27,532 $ 23,383 $ 76,225 $ 68,180
=========== =========== =========== ===========
Earnings per share - Basic...................................... $ 0.62 $ 0.53 $ 1.72 $ 1.54
=========== =========== =========== ===========
Earnings per share - Diluted.................................... $ 0.61 $ 0.52 $ 1.68 $ 1.50
=========== =========== =========== ===========
Weighted average number of
common shares outstanding--Basic.............................. 44,256,002 44,414,799 44,191,591 44,329,592
=========== =========== =========== ===========
Weighted average number of common
shares outstanding--Diluted................................... 45,247,634 45,401,778 45,242,772 45,332,089
=========== =========== =========== ===========
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(IN THOUSANDS)
(unaudited)
For the Nine Months
Ended September 30,
------------------------
2006 2005
---------- ------------
OPERATING ACTIVITIES:
Net income...................................................... $ 76,225 $ 68,180
Adjustments to reconcile net income to net cash
provided by operating activities:
Stock compensation expense.................................. 7,927 18
Write-off deferred financing fees........................... -- 197
Write-down of investment in securities...................... 1,000 --
Write-down of fixed assets.................................. 300 872
Deferred income taxes....................................... 7,814 11,172
Excess tax benefit of stock options exercised............... (7,783) 6,098
Depreciation................................................ 17,636 14,564
Amortization................................................ 2,473 1,171
Changes in operating assets and liabilities, net of
effect of acquisitions:
Accounts receivable......................................... (18,131) (12,249)
Parts and supplies.......................................... (1,266) (234)
Prepaid expenses and other assets........................... (457) (7,805)
Accounts payable............................................ (6,466) 6,614
Accrued liabilities......................................... 34,430 (1,272)
Deferred revenue............................................ 1,015 3,595
---------- ------------
Net cash provided by operating activities....................... 114,717 90,921
---------- ------------
INVESTING ACTIVITIES:
Payments for acquisitions and international
investments, net of cash acquired........................... (142,922) (46,888)
Purchases of short-term investments........................... (2,901) (191)
Proceeds from sale of equipment............................... 601 206
Capital expenditures.......................................... (25,556) (20,140)
---------- ------------
Net cash used in investing activities........................... (170,778) (67,013)
---------- ------------
FINANCING ACTIVITIES:
Proceeds from issuance of note payable........................ 5,953 735
Repayment of long-term debt................................... (13,936) (4,515)
Net repayments of 2001 senior credit facility................. -- (171,353)
Net borrowings of 2005 senior credit facility................. 69,592 182,000
Payments of deferred financing costs.......................... (453) (97)
Principal payments on capital lease obligations............... (669) (608)
Excess tax benefit of stock options exercised................. 7,783 --
Purchase/cancellation of treasury stock....................... (26,060) (47,326)
Proceeds from the exercise of stock options................... 13,122 11,097
---------- ------------
Net cash provided by (used in) financing activities............. 55,332 (30,067)
Effect of exchange rate changes on cash......................... (2,916) 2,104
---------- ------------
Net decrease in cash and cash equivalents....................... (3,645) (4,055)
Cash and cash equivalents at beginning of period................ 7,825 7,850
---------- ------------
Cash and cash equivalents at end of period...................... $ 4,180 $ 3,795
========== ============
Non-cash activities:
Net issuances of common stock for certain acquisitions $ 750 $ --
Net issuances of notes payable for certain acquisitions $ 27,957 $ 37,205
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)
Weighted average Weighted average
Number of exercise price remaining Aggregate
options per share contractual life intrinsic value
---------- --------------- --------------- ---------------
(in years)
Outstanding at December 31, 2005............. 3,592,849 $ 33.23
Granted...................................... 807,899 60.14
Exercised.................................... (675,400) 19.68
Cancelled or expired......................... (174,143) 47.79
---------- ---------------
Outstanding at September 30, 2006............ 3,551,205 $ 41.22 7.2 $ 101,450,504
========== ===============
Exercisable at September 30, 2006............ 1,651,246 $ 30.17 5.8 $ 65,416,543
Three Months Ended Three Months Ended Three Months Ended
September 30, 2006 June 30, 2006 March 31, 2006
------------------- ------------------ ------------------
Stock options granted 24,890 105,703 677,306
Average fair value grant per s $ 18.33 $ 17.13 $ 17.58
Expected volatility (in years) 4.5 4.3 4.4
Expected volatility 28.33% 28.15% 29.08%
Expected dividend yield 0.00% 0.00% 0.00%
Risk free interest rate 4.67% 5.08% 4.83%
Three Months Ended Nine Months Ended
Stock-based compensation expense by caption: September 30, 2006 September 30, 2006
- ---------------------------------------------------------------------- ------------------ ------------------
(in thousands)
Cost of revenues - stock option plan.................................. $ 196 $ 591
Selling, general and administrative - stock option plan.............. 2,382 7,113
Selling, general and administrative - employee stock purchase plan... 75 223
------------------ ------------------
Total $ 2,653 $ 7,927
================== ==================
Three Months Ended Nine Months Ended
September 30, 2005 September 30, 2005
(in thousands, except per share data )
------------------ --------------------
Stock options expense included in net income $ 0 $ 11
------------------ --------------------
As reported net income............................ $ 23,383 $ 68,180
Pro forma impact of stock options and ESPP,
net of tax ....................................... 1,485 4,519
------------------ --------------------
Pro forma net income.............................. $ 21,898 $ 63,661
================== ====================
Earnings per share
Basic-as reported............................ $ 0.53 $ 1.54
================== ====================
Basic-pro forma.............................. $ 0.49 $ 1.44
================== ====================
Diluted-as reported.......................... $ 0.52 $ 1.50
================== ====================
Diluted-pro forma............................ $ 0.49 $ 1.42
================== ====================
Three Months Ended Nine Months Ended
September 30, September 30,
------------------------ ------------------------
2006 2005 2006 2005
----------- ----------- ------------ -----------
Numerator:
Numerator for basic earnings per share
Net Income.......................................... $ 27,532 $ 23,383 $ 76,225 $ 68,180
----------- ----------- ----------- -----------
Denominator:
Denominator for basic earnings per share
Weighted average shares............................ 44,256,002 44,414,799 44,191,591 44,329,592
Effect of dilutive securities:
Employee stock options............................. 991,348 986,812 1,050,918 1,002,425
Warrants........................................... 284 167 263 72
----------- ----------- ----------- -----------
Dilutive potential shares............................ 991,632 986,979 1,051,181 1,002,497
----------- ----------- ----------- -----------
Denominator for diluted earnings
per share-adjusted weighted
average shares and after assumed
conversions.......................................... 45,247,634 45,401,778 45,242,772 45,332,089
=========== =========== =========== ===========
Earnings per share - Basic............................. $ 0.62 $ 0.53 $ 1.72 $ 1.54
=========== =========== =========== ===========
Earnings per share - Diluted........................... $ 0.61 $ 0.52 $ 1.68 $ 1.50
=========== =========== =========== ===========
Three Months Ended Nine Months Ended
September 30, September 30,
--------------------- ---------------------
2006 2005 2006 2005
--------- --------- --------- ---------
Net Income........................................ $ 27,532 $ 23,383 $ 76,225 $ 68,180
Other comprehensive income (loss):
Currency translation adjustments............. 1,174 640 3,762 (1,444)
Net gain on derivative instruments........... 226 0 131 0
--------- --------- --------- ---------
Other comprehensive income (loss)........ 1,400 640 3,893 (1,444)
--------- --------- --------- ---------
Total comprehensive income........................ $ 28,932 $ 24,023 $ 80,118 $ 66,736
========= ========= ========= =========
United Foreign
States Countries Total
---------- ----------- -----------
Balance as of January 1, 2006 .................... $ 621,496 $ 63,673 $ 685,169
Change due to currency fluctuation ............... 0 7,273 7,273
Allocated to intangibles ......................... (21,062) (45,986) (67,048)
Changes in Goodwill for
2005 acquistions ............................. 2,310 (765) 1,545
Goodwill on 2006 acquisitions ................... 16,087 137,693 153,780
---------- ----------- -----------
Balance as of September 30, 2006 ................. $ 618,831 $ 161,888 $ 780,719
========== =========== ===========
Three Months Ended Nine Months Ended
September 30, September 30,
-------------------- --------------------
2006 2005 2006 2005
--------- --------- --------- ---------
(in thousands) (in thousands)
Medical waste management services............ $ 140,525 $ 125,530 $ 413,430 $ 365,477
Pharmaceutical return services............... 15,854 1,452 42,925 2,885
--------- --------- --------- ---------
Total revenue................................ 156,379 126,982 456,355 368,362
--------- --------- --------- ---------
Net interest expense......................... 6,273 2,738 17,380 7,394
Income before income taxes................... 38,259 35,591 108,044 105,802
Income taxes................................. 16,452 14,003 45,600 41,564
--------- --------- --------- ---------
Net income................................... $ 21,807 $ 21,588 $ 62,444 $ 64,238
========= ========= ========= =========
Depreciation and amortization................ $ 5,580 $ 3,908 $ 14,986 $ 11,686
Three Months Ended Nine Months Ended
September 30, September 30,
-------------------- --------------------
2006 2005 2006 2005
-------------------- --------------------
(in thousands) (in thousands)
Medical waste management services............ $ 46,728 $ 25,687 $ 124,146 $ 73,867
Proprietary equipment and technology
license sales............................ 160 507 439 673
--------- --------- --------- ---------
Total revenue................................ 46,888 26,194 124,585 74,540
--------- --------- --------- ---------
Net interest expense......................... 1,047 285 2,592 1,026
Income before income taxes................... 6,876 2,849 16,916 6,315
Income taxes................................. 1,151 1,054 3,135 2,373
--------- --------- --------- ---------
Net income................................... $ 5,725 $ 1,795 $ 13,781 $ 3,942
========= ========= ========= =========
Depreciation and amortization................ $ 1,521 $ 1,457 $ 5,123 $ 4,049
Three Months Ended September 30,
---------------------------------------
2006 2005
------------------ ------------------
$ % $ %
-------- -------- -------- --------
Revenues............................................... $203,267 100.0 $153,176 100.0
Cost of revenues....................................... 107,700 53.0 81,513 53.2
Depreciation........................................... 5,044 2.5 4,075 2.7
-------- -------- -------- --------
Total cost of revenues................................. 112,744 55.5 85,588 55.9
-------- -------- -------- --------
Gross profit........................................... 90,523 44.5 67,588 44.1
Selling, general and
administrative expenses.............................. 34,912 17.2 23,300 15.2
Depreciation........................................... 879 0.4 791 0.5
Amortization........................................... 1,178 0.6 499 0.3
Acquisition related expenses........................... 519 0.3 174 0.1
-------- -------- -------- --------
Total selling, general and administrative expenses..... 37,488 18.4 24,764 16.2
-------- -------- -------- --------
Write-down of fixed assets............................. 0 0.0 872 0.6
-------- -------- -------- --------
Income from operations................................. 53,035 26.1 41,952 27.4
-------- -------- -------- --------
Net income............................................. 27,532 13.5 23,383 15.3
Earnings per share-diluted............................. $ 0.61 $ 0.52
Nine Months Ended September 30,
--------------------------------------
2006 2005
------------------ ------------------
$ % $ %
-------- -------- -------- --------
Revenues............................................... $580,940 100.0 $442,902 100.0
Cost of revenues....................................... 309,426 53.3 236,856 53.5
Depreciation........................................... 14,677 2.5 12,246 2.8
-------- -------- -------- --------
Total cost of revenues................................. 324,103 55.8 249,102 56.2
-------- -------- -------- --------
Gross profit........................................... 256,837 44.2 193,800 43.8
Selling, general and
administrative expenses.............................. 101,549 17.5 65,965 14.9
Depreciation........................................... 2,959 0.5 2,318 0.5
Amortization........................................... 2,473 0.4 1,171 0.3
Acquisition related costs.............................. 1,814 0.3 444 0.1
-------- -------- -------- --------
Total selling, general and administrative expenses..... 108,795 18.7 69,898 15.8
-------- -------- -------- --------
Write-down of fixed assets............................. 300 0.1 872 0.2
-------- -------- -------- --------
Income from operations................................. 147,742 25.4 123,030 27.8
-------- -------- -------- --------
Write-down of security investment...................... 1,000 0.2 0 0.0
Net income............................................. 76,225 13.1 68,180 15.4
Earnings per share-diluted............................. $ 1.68 $ 1.50
OTHER INFORMATION
Maximum
Number (or
Approximate
Dollar
Value) of
Total Shares (or
Number of Shares Units) that
Average (or Units) May Yet Be
Total Price Purchased as Part Purchased
Number of Shares Paid per of Publicly Under the
(or Units) Share Announced Plans Plans or
Period Purchased (or Unit) or Programs Programs
- ------------------------------------------------------------------------------------------------------------
January 1 - January 31, 2006 181,800 57.99 181,800 1,914,700
February 1 - February 28, 2006 11,300 58.01 11,300 1,903,400
March 1 - March 31, 2006 0 0.00 0 1,903,400
April 1 - April 30, 2006 0 0.00 0 1,903,400
May 1 - May 31, 2006 2,000 59.45 2,000 1,901,400
June 1 - June 30, 2006 60,600 62.71 60,600 1,840,800
July 1 - July 31, 2006 164,945 62.45 164,945 1,675,855
August 1 - August 31, 2006 0 0.00 0 1,675,855
September 1 - September 30, 2006 9,913 67.50 9,913 1,665,942
|
STERICYCLE, INC. |
|
|
(Registrant) |
|
|
By: |
/s/ Frank J.M. ten Brink |
|
Frank J.M. ten Brink |
|
|
Executive Vice President and Chief Financial Officer (Principal Financial and Accounting Officer) |
Exhibit 31.1
Rule 13a-14(a)/15d-14(a) Certification
Mark C. Miller
President and Chief Executive Officer
I, Mark C. Miller, certify that:
1. I have reviewed this quarterly report on Form 10-Q of Stericycle, Inc.;
2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operation and cash flows of the registrant as of, and for, the periods presented in this report.
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant, and have:
(a) designed such disclosure controls and procedure, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's third fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting.
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
Date: November 8, 2006.
/s/ Mark C. Miller
Mark C. Miller
President and Chief Executive Officer
Stericycle, Inc.
Exhibit 31.2
Rule 13a-14(a)/15d-14(a) Certification
Frank J.M. ten Brink
Executive Vice President and Chief Financial Officer
I, Frank J.M. ten Brink, certify that:
1. I have reviewed this quarterly report on Form 10-Q of Stericycle, Inc.;
2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operation and cash flows of the registrant as of, and for, the periods presented in this report.
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant, and have:
(a) designed such disclosure controls and procedure, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's third fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting.
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
Date: November 8, 2006.
/s/ Frank J.M. ten Brink
Frank J.M. ten Brink
Executive Vice President and
Chief Financial Officer
Stericycle, Inc.
Exhibit 32
SECTION 1350 CERTIFICATION
In reference to this quarterly report on Form 10-Q of Stericycle, Inc. we, Mark C. Miller, President and Chief Executive Officer of the registrant, and Frank J.M. ten Brink, an Executive Vice President and the Chief Financial Officer of the registrant, certify as follows, pursuant to 18 U.S.C. 1350 (as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002):
(a) the report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and
(b) the information contained in the report fairly presents, in all material respects, the financial condition and results of operations of the registrant.
Date: November 8, 2006.
/s/ Mark C. Miller
Mark C. Miller
President and Chief Executive Officer
Stericycle, Inc.
/s/ Frank J.M. ten Brink
Frank J.M. ten Brink
Executive Vice President
and Chief Financial Officer
Stericycle, Inc.